Back to Search
FRITS VAN RHEE, MD
MD
Hematology & Oncology Physician
NPI: 1972693455IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
E-2781(AR)
CMS Specialties
PrimaryHEMATOLOGY
Education
OTHER
Class of 1985
Research & Publications (20)
Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
PMID 17984985·Nat Clin Pract Oncol·2008
2-rct
Con: allogeneic transplantation in multiple myeloma.
PMID 16728948·Clin Adv Hematol Oncol·2006
8-other
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
PMID 15671442·Blood·2005
8-other
Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation.
PMID 11953036·Cytotherapy·2002
6-review
Identification and isolation of Ag-specific T cells by flow sorting.
PMID 11953050·Cytotherapy·2002
8-other
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
PMID 19443657·Blood·2009
3-trial
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
PMID 19389881·Blood·2009
8-other
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
PMID 19515721·Blood·2009
3-trial
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
PMID 19344415·Br J Haematol·2009
8-other
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
PMID 18492953·Blood·2008
3-trial
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
PMID 18669874·Blood·2008
3-trial
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
PMID 18728024·Haematologica·2008
2-rct
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
PMID 18470907·Cancer·2008
8-other
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more.
PMID 18305551·Leukemia·2008
8-other
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
PMID 18371114·Br J Haematol·2008
3-trial
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
PMID 18432260·Leukemia·2008
3-trial
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
PMID 18433012·Cancer·2008
3-trial
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
PMID 18451245·Clin Cancer Res·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4301 W MARKHAM ST # 783
LITTLE ROCK, AR 72205 - Phone
- (501) 686-8000
Quick Facts
- NPI
- 1972693455
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile